Follow-up prostate cancer treatments after radical prostatectomy: A population-based study

Journal of the National Cancer Institute

Volumn 88, Issue 3-4, 1996, Pages 166-172

  Lu Yao, Grace L ^a,e   Potosky, Arnold L ^b   Albertsen, Peter C ^c   Wasson, John H ^a   Barry, Michael J ^d   Wennberg, John E ^a  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; CONTINENTAL POPULATION GROUPS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; SEER PROGRAM; UNITED STATES;

EID: 0030020434     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.3-4.166     Document Type: Article

References (40)

1. Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995 [published erratum appears in CA Cancer J Clin 1995;45:127-8]. CA Cancer J Clin 1995,45:8-30
2. Consensus conference. The management of clinically localized prostate cancer. JAMA 1987;258:2727-30.
3. Whitmore WF Jr. Management of clinically localized prostatic cancer: an unresolved problem [editorial; comment] [see comment citations in Medline]. JAMA 1993;269:2676-7.
4. Chodak GW, Tristed RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer [see comment citations in Medline]. N Engt J Med 1994; 330.242-8.
5. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team [see comment citations in Medline]. JAMA 1993;269:2650-8.
6. Sherman CR, Potosky AL, Weis KA, Ferguson JH. The Consensus Development Program. Detecting changes in medical practice following a consensus conference on the treatment of prostate cancer. Int J Technol Assess Health Care 1992;8:683-93.
7. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team [see comment citations in Medline]. JAMA 1993;269:2633-6.
8. Barry MJ. Proving early detection and treatment of prostate cancer does more good than harm: the need to support randomized trials actively [editorial; comment] [see comment citations in Medline]. J Urol 1994; 152(5 Pt 2):1903-4.
9. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer [see comment citation in Medline]. J Urol 1994; 152(5 Pt 2): 1910-4
10. Norlén B. Swedish randomized trial of radical prostatectomy versus watchful waiting. Can J Oncol 1994;4(suppl):38-40.
11. Murphy GP. Report on the American Urologie Association/American Cancer Society scientific seminar on the detection and treatment of early-stage prostate cancer. CA Cancer J Clin 1994,44:91-5.
12. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer [see comment citation in Medline]. J Urol 1994;152(5 Pt 2):1837-42.
13. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years [see comment citation in Medline]. J Urol 1994;152(5 Pt 2):1831-6.
14. Scher HI, Fossa S. Prostate cancer in the era of prostate-specific antigen. Curr Opin Oncol 1995;7:281.
15. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993,31:732-48.
16. Surveillance Epidemiology and End Results (SEER) Program. Public use tape (1973-1990). Bethesda (MD): Surveillance Program, Cancer Statistics Branch, Division of Cancer Prevention and Control. National Cancer Institute. 1993.
17. SEER Cancer Statistics Review, 1973-1991: tables and graphs. Bethesda (MD): National Cancer Institute, 1994.
18. Fisher ES, Baron JA, Malenka DJ, Barrett J, Bubolz TA. Overcoming potential pitfalls in the use of Medicare data for epidemiologic research. Am J Public Health 1990;80:1487-90.
19. Division of Quality Control Management, American Hospital Association. International Classification of Diseases, ninth revision, clinical modification. Chicago (IL). American Hospital Publishing Inc., 1989.
20. Physicians' common procedural terminology, 4th edition. Chicago (IL): American Medical Association, 1994.
21. Shambaugh EM, Weiss MA Summary staging guide for the Cancer Surveillance, Epidemiology and End Results Reporting (SEER) Program. Bethesda (MD): Public Health Service, U.S. Department of Health and Human Services, National Institutes of Health, 1986.
22. The SEER Program code manual. Bethesda (MD): National Cancer Institute, 1992.
23. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40-373-83.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9.
26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
27. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multi-variate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup [see comment citation in Medline]. J Urol 1993; 149:1478-81.
28. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy [see comment citation in Medline]. Int J Radiat Oncol Biol Phys 1995;31:237-45.
29. Zincke H, Bergstralh EI, Blute ML, Myers RP, Barrett DM, Lieber MM, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution [see comment citation in Medline]. J Clin Oncol 1994;12:2254-63.
30. Hinman F Jr. Screening for prostatic carcinoma. J Urol 1991;145:126-9.
31. Lange PH. Controversies in management of apparently localized carcinoma of prostate. Urology 1989;34(4 Suppl ):13-8.
32. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment following radical prostatectomy: the national Medicare experience: 1988-1990 (updated June 1993). urology 1993;42:622-9.
33. Catalona WJ, Dresner SM. Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 1985; 134:1149-51.
34. Eggleston JC, Walsh PC. Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol 1985; 134.1146-8.
35. Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987;138:1407-12.
36. Leandri P, Rossignol G, Gautier JR, Ramon J. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992;147(3 Pt 2):883-7.
37. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
38. Catalona WJ, Smith DS, Ratliff TL, Basler JW Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening [see comment citation in Medline]. JAMA 1993;270:948-54.
39. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer [see comment citation in Medline]. JAMA 1994;271:368-74.
40. Fleming C, Fisher ES. Chang CH, Bubolz TA, Malenka DJ. Studying outcomes and hospital utilization in the elderly. The advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care 1992; 30:377-91.